ADIM
AMRN

Alpha DNA Investment Management’s Amarin Corp AMRN Stock Holding History

Alpha DNA Investment Management’s Portfolio AMRN Stock Details AMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4
Closed – – 129
2021
Q1 		$0 Hold
4
– – ﹤0.01% 680
2020
Q4 		$0 Buy
+4
New +$386 ﹤0.01% 583

Other funds holding AMRN

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
SI
SCP Investment Orinda, California $90.3M AUM 31.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Alpha DNA Investment Management's AMRN Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Amarin Corp (AMRN) in Q2 2021, closing a stake of 4 shares.

Alpha DNA Investment Management first reported a position in AMRN in Q4 2020 and held it in 2 quarters. The position peaked at $0 in Q1 2021. 233 funds tracked by Wall St. Rank hold AMRN as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Amarin Corp position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 4 Amarin Corp shares in Q2 2021.
  • Alpha DNA Investment Management first reported a position in Amarin Corp in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's Amarin Corp position peaked at $0 in Q1 2021.
  • 233 funds tracked by Wall St. Rank held Amarin Corp as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.